–Document will inform development of report for public deliberation by the Midwest CEPAC–

August 1, 2016 – The Institute for Clinical and Economic Review (ICER) has posted a draft scoping document that will inform a report on drug therapies for rheumatoid arthritis. The document will be open to public comment for three weeks.

The draft scoping document was developed with input from a number of patient groups, clinical experts, and other stakeholders. In addition, stakeholders were invited to submit any information relevant to the review during a three-week long open input period that began with the announcement of the topic. While an initial announcement of the topic indicated that ICER may consider treatments for psoriatic arthritis alongside those for rheumatoid arthritis, feedback received from patient groups, manufacturers, and other stakeholders strongly indicated that the two disease areas have such important differences in patient-centered outcomes that they should be considered separately. ICER will focus only on rheumatoid arthritis for this review and will consider reviewing treatments for psoriatic arthritis as a future topic.

The scoping document will guide development of a report that will serve as the basis for deliberation and discussion at an upcoming public meeting of the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC) to be held on January 26, 2017. The Midwest CEPAC is a core program of ICER.

The draft scoping document will be open to public comment for a period of three weeks, during which time we invite all interested stakeholders, including patients, providers, payers, or manufacturers, to submit comments and suggested refinements to the scope to ensure all perspectives are adequately considered. All comments should be emailed to publiccomments@icer-review.org and must be received by Monday, August 22, 2016 at 5:00PM CST. More information about submitting a public comment, including formatting specifications, is available on the ICER website.

Following the public comment period, a revised scoping document will be posted on or about August 29, 2016. The revised scope will guide development of a Draft Evidence Report, scheduled to be posted on or about November 14, 2016. Once posted, the Draft Evidence Report will be open to a four-week public comment period, during which time we again invite all interested stakeholders to provide comments, suggestions, and refinements to the report.

During the January 26, 2017 Midwest CEPAC public meeting, the independent Council will vote on key questions raised in the report, and a policy roundtable of experts in the field will discuss recommendations for how best to apply the evidence to policy and practice.

Additional key dates for the draft report, as well as further information about the May meeting, are included below:

August 1st:  Draft scoping document posted

August 1st-August 22nd: Public Comment Period on Draft Scoping Document

August 29th: Final scoping document posted

November 14th: Initial Draft Evidence Report and Draft Voting Questions Posted

November 14th – December 13th: Public Comment Period on Draft Evidence Report and Draft Voting Questions

January 4th: Evidence Report Posted

January 26th: Public Meeting of the Midwest CEPAC

On or about February 2nd: Final Report Posted

Meeting Details

Date: January 26, 2017

Location: St. Louis, MO

Additional details will be posted to the ICER website as they become available.

About ICER

The Institute for Clinical and Economic Review (ICER) is an independent non-profit research institute that produces reports analyzing the evidence on the effectiveness and value of drugs and other medical services. ICER’s reports include evidence-based calculations of prices for new drugs that accurately reflect the degree of improvement expected in long-term patient outcomes, while also highlighting price levels that might contribute to unaffordable short-term cost growth for the overall health care system.

ICER’s reports incorporate extensive input from all stakeholders and are the subject of public hearings through three core programs: the California Technology Assessment Forum (CTAF), the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), and the New England Comparative Effectiveness Public Advisory Council (New England CEPAC). These independent panels review ICER’s reports at public meetings to deliberate on the evidence and develop recommendations for how patients, clinicians, insurers, and policymakers can improve the quality and value of health care. For more information about ICER, please visit ICER’s website.